Physician profile
Edward Thorburn Wright
NPI 1164428140
$1,246.60
in general payments reported to CMS, 2019-2025
29 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $37.15 · 2021: $407 · 2022: $197 · 2023: $227 · 2024: $132 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $210.87 | 2019-2021 | |
| Vifor Pharma, INC. | $89.25 | 2020-2023 | Korsuva, Veltassa |
| Pfizer INC. | $86.87 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.33 | 2021-2025 | |
| Blue Earth Diagnostics | $74.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.70 | 2023 | Lynparza, Keytruda, Welireg |
| Abbvie INC. | $58.95 | 2022-2025 | Botox |
| Axonics, INC. | $51.74 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $51.21 | 2025 | Purified Cortrophin Gel |
| Accord Healthcare, INC. | $49.89 | 2022-2024 | |
| C. R. Bard, INC. & Subsidiaries | $43.65 | 2019 | |
| Sumitomo Pharma America, INC. | $43.43 | 2023-2024 | Gemtesa, Orgovyx |
| Welch Allyn | $34.73 | 2021 | |
| Dendreon Pharmaceuticals LLC | $34.05 | 2024 | Provenge |
| Baxter Healthcare | $32.56 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $26.73 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $23.11 | 2022 | |
| Allergan, INC. | $20.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.92 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.75 | 2022 | |
| Myovant Sciences INC. | $17.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.10 | 2025 | Jardiance |
| Procept Biorobotics Corporation | $16.59 | 2025 | |
| Coloplast Corp | $16.43 | 2019 | |
| Rochester Medical Corporation | $16.04 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.79 | 2021 | |
| Amgen INC. | $11.79 | 2019 | |
| Olympus America INC. | $11.78 | 2022 | |
| Travere Therapeutics, INC. | $9.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.